New pill targets Tough-to-Treat breast cancer in early trial
NCT ID NCT05654532
Summary
This is the first human study of an experimental oral drug called AC699 for people with advanced ER+/HER2- breast cancer that has progressed after standard treatments. The main goals are to find a safe dose, understand how the body processes the drug, and look for early signs that it can shrink tumors. The study will enroll about 100 adults who have already tried other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 01
Nashville, Tennessee, 37203, United States
-
Site 02
Sarasota, Florida, 34232, United States
-
Site 03
Houston, Texas, 77030, United States
-
Site 04
Vancouver, Washington, 98684, United States
-
Site 05
Norfolk, Virginia, 23502, United States
-
Site 06
Rockville, Maryland, 21044, United States
-
Site 07
Orlando, Florida, 32746, United States
-
Site 08
Denver, Colorado, 80218, United States
-
Site 09
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.